Shots:
- Surface Oncology to receive ~$85 M upfront and ~$730 M as milestones along with royalties on net sales of SRF813
- GSK to get an exclusive right to develop and commercialize Surface Oncology’s preclinical program, SRF813
- SRF813 is an IgG1 Ab targeting PVRIG (also k/a CD112), currently in IND-enabling studies with anticipated IND submission in 2021
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Emergency Physicians Monthly
The post GSK Signs an Exclusive License Agreement with Surface Oncology to Develop and Commercialize SRF813 first appeared on PharmaShots.
